Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, an initial safety run-in period has been completed in 12 subject.
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.